$TARS

3 stories mentioning TARSUpdated just now

Every FINWIRES story that references TARS, newest first.

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) eased 0.2%.In corporate news, short seller Culper Research said Wednesday it has taken a short position in Tarsus Pharmaceuticals (TARS), alleging the commercialization of Xdemvy relies on a Medicare copay assistance structure that "raises serious Anti-Kickback Statute concerns." Tarsus shares were down 3.6%.Can-Fite BioPharma (CANF) shares surged 56% after it said its phase 2a trial of Namodenoson in advanced pancreatic cancer met its primary safety endpoint and showed durable survival in a subset of heavily pretreated patients.Hims & Hers Health (HIMS) shares jumped past 8% after BofA Securities raised its price target to $36 from $25, while keeping its neutral rating.BridgeBio Pharma (BBIO) has raised up to $1 billion in convertible preferred equity led by Sixth Street, with participation from HealthCare Royalty, a KKR (KKR) business, to fund upcoming product launches and pipeline development. BridgeBio shares were up 0.3%.

$BBIO$CANF$HIMS$TARS

Sectors2h ago

Sector Update: Healthcare

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index increasing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, short seller Culper Research said Wednesday it has taken a short position in Tarsus Pharmaceuticals (TARS), alleging the commercialization of Xdemvy relies on a Medicare copay assistance structure that "raises serious Anti-Kickback Statute concerns." Tarsus shares were down 3.6%.

$TARS

Wire3h ago

Tarsus Pharmaceuticals Faces Medicare Copay Allegations From Culper Research; Shares Fall

Short seller Culper Research said Wednesday it has taken a short position in Tarsus Pharmaceuticals (TARS), alleging the commercialization of Xdemvy relies on a Medicare copay assistance structure that "raises serious Anti-Kickback Statute concerns."Culper alleged Tarsus funds a charitable foundation that subsidizes Medicare copays for Xdemvy patients and said the arrangement bears "many of the attributes of the arrangements that have been prosecuted" by the US Department of Justice.The short seller also argued Tarsus' addressable market is "a fraction (~20%) of the Company's claims" and projected Xdemvy revenue would "peak below $800 million at best," compared with the company's long-term target of more than $2 billion.Culper further argued that analysts underestimate Tarsus' patient assistance costs and said the company's profitability "will never materialize" because those expenses are higher than Wall Street expects.Tarsus did not immediately respond to' request for comment.Shares of Tarsus were down more than 6% in Wednesday afternoon trading.Price: $59.06, Change: $-3.88, Percent Change: -6.16%

$TARS

Track with the FINWIRES app suite

FolioX

Track TARS in your portfolio

WheelAI

Analyze TARS options with the wheel strategy

StockInsider

See market sentiment on TARS